NCT05623774View on ClinicalTrials.gov

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions
CML
Interventions
DRUG

Imatinib Mesylate

400mg tablet

DRUG

IkT-001Pro

100mg or 400mg tablet

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

ABLi Therapeutics, Inc.

INDUSTRY